DT Cloud Acquisition Corporation functions as a special purpose acquisition company, primarily established to complete a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or another similar business combination with an identified entity. The company has recently entered into a definitive agreement for a business combination with Maius Pharmaceutical Co., Ltd., a biopharmaceutical firm specializing in innovative formulations and targeted small-molecule chemical drugs, with a focus on anticancer, autoimmune, and anti-infective medications. This transaction is anticipated to conclude in the initial half of 2025. Nevertheless, DT Cloud Acquisition Corporation recently received notification from Nasdaq regarding its non-compliance with listing requirements, which threatens a suspension of trading on November 21, 2025, pending any appeal. Established in 2022, the company maintains its headquarters in London, United Kingdom, and operates as a subsidiary of DT Cloud Capital Corp.